These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 2929999)

  • 41. Pharmacokinetics of an infusion of propofol during cardiac surgery.
    Massey NJ; Sherry KM; Oldroyd S; Peacock JE
    Br J Anaesth; 1990 Oct; 65(4):475-9. PubMed ID: 2248815
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intravenous dantrolene does not exhibit calcium channel blocking effects on the cardiac conduction system in humans.
    Kentsch M; Roewer N; Kunze KP; Kuck KH
    Anesthesiology; 1991 Oct; 75(4):583-7. PubMed ID: 1928768
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Exploring the pharmacokinetics of oral ketamine in children undergoing burns procedures.
    Brunette KE; Anderson BJ; Thomas J; Wiesner L; Herd DW; Schulein S
    Paediatr Anaesth; 2011 Jun; 21(6):653-62. PubMed ID: 21355949
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ryanodex--A New Dantrolene Formulation for Malignant Hyperthermia.
    Med Lett Drugs Ther; 2015 Jul; 57(1472):100. PubMed ID: 26147894
    [No Abstract]   [Full Text] [Related]  

  • 45. Intranasal administration of dantrolene increased brain concentration and duration.
    Wang J; Shi Y; Yu S; Wang Y; Meng Q; Liang G; Eckenhoff MF; Wei H
    PLoS One; 2020; 15(3):e0229156. PubMed ID: 32160210
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Malignant hyperthermia syndrome.
    Waterman PM
    Am J Ophthalmol; 1981 Oct; 92(4):461-5. PubMed ID: 7294108
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dantrolene--a review of its pharmacology, therapeutic use and new developments.
    Krause T; Gerbershagen MU; Fiege M; Weisshorn R; Wappler F
    Anaesthesia; 2004 Apr; 59(4):364-73. PubMed ID: 15023108
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Adverse effects and recovery after total intravenous anesthesia in children].
    Drasković B; Cvejanov M
    Med Pregl; 1998; 51(1-2):68-72. PubMed ID: 9531778
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Anaesthesia in a patient susceptible to malignant hyperthermia (author's transl)].
    Schuh FT; Maier C
    Anaesthesist; 1982 May; 31(5):245-7. PubMed ID: 7103032
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effect of dantrolene sodium on rat skeletal muscle in relation to the plasma concentration.
    Meyler WJ; Mols-Thurkow I; Scaf AH; Sargo S; Wesseling H
    Eur J Pharmacol; 1979 Feb; 53(4):335-42. PubMed ID: 421731
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Management of otolaryngic patients susceptible to malignant hyperthermia without dantrolene.
    Derkay CS; Grundfast KM
    Otolaryngol Head Neck Surg; 1991 Nov; 105(5):680-6. PubMed ID: 1754251
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Postpartum uterine atony after intravenous dantrolene.
    Weingarten AE; Korsh JI; Neuman GG; Stern SB
    Anesth Analg; 1987 Mar; 66(3):269-70. PubMed ID: 3826671
    [No Abstract]   [Full Text] [Related]  

  • 53. [A case of high dose administration of propofol].
    Nishioka H; Kinuwaki H; Shimoda O; Terasaki H
    Masui; 2000 Oct; 49(10):1142-4. PubMed ID: 11075566
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Malignant hyperthermia treated without dantrolene.
    Stranix ND; Hutchinson R; Liversidge P; Ssenoga A; Clark NJ
    Trop Doct; 1994 Oct; 24(4):186-7. PubMed ID: 7801376
    [No Abstract]   [Full Text] [Related]  

  • 55. Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity.
    Ward A; Chaffman MO; Sorkin EM
    Drugs; 1986 Aug; 32(2):130-68. PubMed ID: 3527659
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Postoperative respiratory depression thought to be due to oral dantrolene pretreatment in a malignant hyperthermia-susceptible patient].
    Hara Y; Kato A; Horikawa H; Kato Y; Ichiyanagi K
    Masui; 1988 Apr; 37(4):483-7. PubMed ID: 3398231
    [No Abstract]   [Full Text] [Related]  

  • 57. Availability of dantrolene in Canadian hospitals.
    Duncan PG
    Can Anaesth Soc J; 1985 May; 32(3 Pt 1):205-9. PubMed ID: 4005670
    [No Abstract]   [Full Text] [Related]  

  • 58. Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery.
    Westmoreland CL; Hoke JF; Sebel PS; Hug CC; Muir KT
    Anesthesiology; 1993 Nov; 79(5):893-903. PubMed ID: 7902033
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Treatment of malignant hyperthermia by dantrolene sodium administered through a nasogastric tube].
    Nagase M; Naganuma Y; Ryo K; Sato N; Kawashima Y
    Masui; 1984 Sep; 33(9):1021-6. PubMed ID: 6512969
    [No Abstract]   [Full Text] [Related]  

  • 60. Repeated nonanesthetic malignant hyperthermia reactions in a child.
    Cummings T; Der T; Karsli C
    Paediatr Anaesth; 2016 Dec; 26(12):1202-1203. PubMed ID: 27562486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.